Remnant Liver Tumor Growth Activity During Treatment Associating Liver Partition and Portal Vein Occlusion for Staged Hepatectomy (ALPPS)

被引:8
作者
Kikuchi, Yutaro [1 ]
Hiroshima, Yukihiko [1 ]
Matsuo, Kenichi [1 ]
Murakami, Takashi [1 ]
Kawaguchi, Daisuke [1 ]
Endo, Itaru [2 ]
Yamazaki, Kazuto [3 ]
Ishida, Yasuo [3 ]
Tanaka, Kuniya [1 ]
机构
[1] Teikyo Univ, Chiba Med Ctr, Dept Surg, 3426-3 Anesaki, Ichihara, Chiba 2990111, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol Surg, Yokohama, Kanagawa, Japan
[3] Teikyo Univ, Chiba Med Ctr, Div Diagnost Pathol, Chiba, Japan
基金
日本学术振兴会;
关键词
ALPPS; 2-stage hepatectomy; Tumor volume; Kinetic growth; LIGATION; EMBOLIZATION; METASTASES; CANCER; HYPERTROPHY; FAILURE;
D O I
10.1007/s11605-017-3523-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We compared tumor growth activity during treatment associating liver partition and portal vein occlusion for staged hepatectomy (ALPPS) with that in classical 2-stage hepatectomy. Short-term outcomes, serial changes in volume of the future liver remnant (FLR), and tumor growth activity during the treatment period were compared between 12 patients treated with ALPPS and 20 patients treated with 2-stage hepatectomy for colorectal liver metastases. This study was registered in UMIN Clinical Trials Registry (registration number, UMIN000018622). The FLR hypertrophy ratio at 1 week after the first operation was greater in the ALPPS group (1.43 +/- 0.24) than the 2-stage group (1.21 +/- 0.28, P = 0.043). The mean kinetic growth rate (mKGR) of tumors in the ALPPS group (0.548 +/- 7.29 mL/day) did not differ significantly from that in the 2-stage group (-3.53 +/- 7.02 mL/day) in the first week after the initial procedure (P = 0.210). However, mKGR between 1 and 3 weeks after the first procedure (1.29 +/- 2.34 mL/day) was significantly greater than that in first week after the procedure in the 2-stage group (P = 0.034). ALPPS induces a rapid FLR volume increase while avoiding remnant tumor progression.
引用
收藏
页码:1851 / 1858
页数:8
相关论文
共 21 条
[1]   Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[2]   Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): What Is Gained and What Is Lost? [J].
Aloia, Thomas A. ;
Vauthey, Jean-Nicolas .
ANNALS OF SURGERY, 2012, 256 (03) :E9-E9
[3]   New method of hepatic regeneration [J].
Alvarez, Fernando A. ;
Iniesta, Jose ;
Lastiri, Jose ;
Ulla, Marina ;
Bonadeo Lassalle, Fernando ;
de Santibanes, Eduardo .
CIRUGIA ESPANOLA, 2011, 89 (10) :645-649
[4]   Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and living donor liver transplant? A multicentre analysis [J].
Croome, Kristopher P. ;
Hernandez-Alejandro, Roberto ;
Parker, Maile ;
Heimbach, Julie ;
Rosen, Charles ;
Nagorney, David M. .
HPB, 2015, 17 (06) :477-484
[5]   Induction of Tumor Growth After Preoperative Portal Vein Embolization: Is It a Real Problem? [J].
de Graaf, Wilmar ;
van den Esschert, Jacomina W. ;
van Lienden, Krijn P. ;
van Gulik, Thomas M. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (02) :423-430
[6]   Playing Play-Doh to Prevent Postoperative Liver Failure The "ALPPS" approach [J].
de Santibanes, Eduardo ;
Clavien, Pierre-Alain .
ANNALS OF SURGERY, 2012, 255 (03) :415-417
[7]   How to Avoid Postoperative Liver Failure: A Novel Method [J].
de Santibanes, Eduardo ;
Alvarez, Fernando A. ;
Ardiles, Victoria .
WORLD JOURNAL OF SURGERY, 2012, 36 (01) :125-128
[8]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[9]   Enhanced tumor growth after portal vein embolization in a rabbit tumor model [J].
Hoekstra, Lisette T. ;
van Lienden, Krijn P. ;
Verheij, Joanne ;
van der Loos, Chris M. ;
Heger, Michal ;
van Gulik, Thomas M. .
JOURNAL OF SURGICAL RESEARCH, 2013, 180 (01) :89-96
[10]   Hepatocyte growth factor scatter factor, its molecular, cellular and clinical implications in cancer [J].
Jiang, W ;
Hiscox, S ;
Matsumoto, K ;
Nakamura, T .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 29 (03) :209-248